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ABSTRACT: The transcriptional downregulation of the SERCA2 gene is stud-
ied using neonatal rat cardiomyocytes stimulated with endothelin-1 to induce
hypertrophy. Liposome-based transfection of cells with a 1.9 kb SERCA2 pro-
moter fragment directed expression of a reporter gene identical to the down-
regulation of genomic SERCA2 expression by endothelin-1. Results of a new
gene gun technology for transient transfection of cardiomyocytes with a RSV-
-galactosidase construct are reported. This new method for propelling DNA-
coated gold beads into cardiomyocytes is extremely suitable for directly testing
promoter/reporter gene DNA constructs since the transfection efficiency (ap-
proximately 10%) appears to be higher than traditional transfection methods.
INTRODUCTION
In both humans and animal models, sustained increased cardiac workload, as a
result, for example, of myocardial infarction, chronic hypertension or valvular insuf-
ficiency, elicits a hypertrophic response of the heart, i.e., an increase in the size of
individual myocytes. The hypertrophic response is characterized by a period of com-
pensation during which remodeling of the heart normalizes systolic wall stress and
basal parameters of contractile function. However, this adaptation carries a price.
This apparent salutory response to excess load is accompanied by reversion to a fetal
program of cardiac gene expression. The upregulation of cardiac neurohumoral hor-
mones, including angiotensin II, catecholamine, endothelin-1 (ET-1), and atrial
natriuretic factor (ANF), is partially involved in mediating the hypertrophic and gene
expression responses. The period of adaptation is followed by a transition to cardiac
failure. The underlying cause of the negative outcome is believed to reside partially
in the reprogramming of gene expression.1−5 This hypothesis is consistent with the
observed relative downregulation of key proteins (indirectly) involved in regulation
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of the uptake and release of Ca2+ from the cardiac sarcoplasmic reticulum: the β-adr-
energic receptor, Ca2+ ATPase (SERCA2), and phospholamban (PL).2−9 On the
other hand, the genes encoding ANF, β-myosin heavy chain, α-skeletal actin, for ex-
ample, are found to be relatively upregulated during hypertrophy.1,5,10,11 The nucle-
ar mechanisms involved in coordinately regulating these cardiac genes during
hypertrophy are fully unknown, although binding sites for several transcription fac-
tors, including serum response factor (SRF), transcription enhancer factor (TEF1),
AP-1 (a heterodimer of jun/fos), and transcription factor Sp1, were shown to be im-
portant for activation of fetal cardiac genes in response to hypertrophy.12−15
As to the upstream signaling events, there is abundant evidence that the Gq-cou-
pled phospholipase C-β, which produces Ca2+-releasing inositol 1,4,5-triphosphate
and protein kinase C activating 1,2-diacylglycerol, are linked to the receptor-medi-
ated Ras and mitogen-activated (MAP) kinase pathways as transducers of hyper-
trophic signaling processes.5,10,14,16 A very recent study of mice, transgenic for
dominant-negative Gq-mediated signaling, convincingly demonstrated that recep-
tor-mediated PLC-β is partially involved in pressure overload–induced hypertrophy
in vivo.17 The known details of the phosphatidylinositol signaling pathway were re-
viewed extensively by us.18
About the same time, there was a report of the discovery of a Ca2+-calmodu-
lin-dependent pathway via calcineurin in the myocardium during hypertrophy that
activated the transcription factor NF-AT3 which, by cooperation with the transcrip-
tion factor GATA4, induces fetal cardiac gene transcription.19 In the latter study it
was hypothesized that the Ca2+ release induced by inositol-1,4,5-triphosphate main-
ly causes calmodulin-calcineurin complex activation.
Most of the previous studies on nuclear factors concern upregulation of cardiac
genes during hypertrophy.10,12−15,19 To initiate studies on the nuclear factors in-
volved in transcriptional downregulation of the SERCA2 gene during hypertrophy,
we employed the model of cultured neonatal rat ventricular myocytes as used suc-
cessfully by many other groups.9,19−21 In this model, we were previously able to
show that ET-1 is a strong inducer of hypertrophy by its increasing effect on the rate
of [3H]leucine incorporation in total protein and protein/DNA ratio.21,22 Recently,
we have isolated, characterized, and tested the activity (by liposome-based transfec-
tion) of an isolated SERCA2 promoter fragment as the first step in the search for the
cis-acting elements and trans-acting factors responsible for downregulation of this
gene during cardiomyocyte hypertrophy. That study22 confirmed the general experi-
ence of other investigators12−15,19 that the use of traditional methods (liposomes) for
transfection of cardiomyocytes can be of value for studying promoter regulation.
However, transfection efficiencies obtained by these methods are still extremely low,
generally no more than one percent, and therefore not suitable for functional testing
of the effects of overexpression of cardiac proteins. Other transfection methods, in-
cluding cationic lipid/plasmid DNA complexes, incubations with “naked” plasmid
DNA, and calcium phosphate (CaPO4) precipitation, do not achieve higher efficien-
cies in cardiac cells.23 A recent report on a new transfection system combined the
convenience of plasmid DNA with the unique targeting properties of adenovirus vec-
tors.24 However, this “component system” gave variable results in our laboratory. In
the mean time, it has been demonstrated by several authors that recombinant repli-
cation-defective human adenovirus can transfect primary cardiac cultures with close
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to 100% efficiency.25−27 These authors could show alterations in cellular Ca2+ tran-
sients after infecting cardiomyocytes with adenovirus overexpressing SERCA2
(Ad.RSV.SERCA2a27 or Ad.CMV.SERCA2a26) and PL (Ad.RSV.PL25). Since re-
combinant adenoviruses overexpressing cardiac Ca2+ handling proteins are time-
consuming to prepare, there is a need for methods with high-efficiency transfection
of cardiomyocytes with plasmid DNA. Recently, a new product for transfection
Fugene6 (Boehringer), and a gold particle–based transfer technology, Helios Gene
Gun (Biorad), have become available.28,29 The Helios Gene Gun uses helium pres-
sure to propel DNA-coated gold particles into cells (biolistics30), originally devel-
oped for in vivo gene transfer into somatic tissues of live animals. Elemental gold
has been chosen for mammalian gene transfer because pure gold is chemically inert
and does not produce cytotoxicity. The high density of gold also permits greater mo-
mentum allowing deeper penetration into target cells. Gene guns have also been used
for plant cells and bacteria because these cells have a hard cell wall, whereas other
methods require the production of protoplasts before gene introduction (reviewed by
Yang and colleagues28). So far, several successful applications using the gene gun to
transfect primary cultures have been reported.28 However, to our knowledge no one
has reported on adapting this method for use with primary cultures of neonatal rat
cardiomyocytes. In this report, we present the first results with the Helios Gene Gun
system in cardiomyocytes using a reporter plasmid harboring the β-galactosidase
(β-Gal) gene under the control of the Rous sarcoma virus (RSV) promoter. We dem-
onstrate that this method is applicable for transfecting beating rat cardiomyocytes
and gives superior results when compared to other—traditional and new—transfec-
tion reagents.
METHODS
DNA Constructs
The SERCA2 5′ upstream regulatory region (1.9 kb, including 0.4 kb of the 5′
UTR of the mRNA) was obtained by screening of a rat genomic library with a probe
derived by PCR based on published rat SERCA2 promoter sequences, as described
in detail elsewhere.22 After restriction mapping of the obtained genomic fragment
(13 kb), the BamHI-NotI fragment (1.9 kb) that was promoter-positive in Southern
analysis was subcloned in a chloramphenicol acetyltransferase (CAT) reporter vec-
tor (pCAT-Basic, Promega) (FIG. 1). The RSV-β-Gal construct was a kind gift from
our Department of Endocrinology and Reproduction. The DNAs were isolated and
purified with the Wizard Midiprep Kit (Promega) in the study aimed at SERCA2
promoter regulation and purified with CsCl, Wizard, or Qiagen (Endofree Plasmid
Maxi Kit; Qiagen, Westburg) for the study aimed at gene gun versus other vehi-
cle-mediated gene transfer.
Transfection and Induction of Hypertrophy by ET-1
Rat neonatal ventricular cardiomyocytes were isolated as described previously,20
preplated, and cultured in 20 cm2 (7.5 × 104 cells/cm2 (SERCA2 promoter regula-
tion)), or 1.8 cm2 dishes (1.5 × 105 cells/cm2 (gene gun–mediated gene transfer)) up
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to 24 h in DMEM/M199 (4:1) supplemented with 5% fetal calf serum and 5% horse
serum (HS). Thereafter, the medium was changed to DMEM/M199 (4:1) with only
5% HS. After 64 h, the medium was changed to serum-free DMEM/M199. Trans-
fection was performed in this serum-free medium by standard CaPO4 (0.5−3 µg
DNA per well, HEPES buffer, pH 7.05, overnight incubation), Fugene6, and DOTAP
methodologies (according to instructions provided by Boehringer Mannheim, Ger-
many) (Fugene6/DNA ratio: 1.5 µl/0.5 µg DNA or 3.6 µl/1.44 µg DNA) (DOTAP/
DNA ratio: 15 µg/5 µg DNA, 18 h) or by gene gun biolistics (see below). Subse-
quently, cells were washed with serum-free DMEM/M199 (4:1) and fresh medium
was added. After 3 h, ET-1 (10 nM) was added for 48 h to induce hypertrophy.9,21,22
Gene Gun–Mediated Biolistics Transfection
The most recent hand-held version of the pulse gene gun (Biorad), which uses he-
lium gas–driven force to propel the gold particles into cultured cells, was employed.
DNA capsules were 1.2-cm pieces of Tefzel® tubing inner-coated with gold particles
and loaded with CsCl-purified DNA. These capsules were then inserted into gene
gun cartridges, which hold 12 capsules, allowing 12 transfections per single loading.
The cartridges were prepared according to the manufacturer’s protocol with slight
but essential modifications.29 Briefly, 200 mg gold particles (0.6 µm diameter) were
suspended and sonicated in 1 ml analytically pure (100% is essential) ethanol to fa-
cilitate the accurate determination of the amount of gold particles needed per prep-
aration. The exact amount of gold needed (4 mg for 40 cartridges) was transferred
to a new tube and dried. Gold particles, DNA, spermidine, and CaCl2 were mixed as
described by the manufacturer (Biorad manual), incubated for 10 minutes, centri-
fuged, washed twice with 100% ethanol, and dried. The DNA-coated particles were
suspended in the appropriate amount of 100% ethanol containing 0.015 mg/ml poly-
vinyl pyrrolidone in a 10-ml glass vial. Thereafter, the solution was transferred into
the Tefzel® tubing, which was already inserted into the tubing prep station, by at-
taching a syringe to the nitrogen inlet. The solution was carefully sucked in just be-
fore the O-ring. The solution was left for 10 min to let the gold settle, followed by
removal of the ethanol using the still-attached syringe. Immediately thereafter, the
tubing chamber was turned by hand and then automatically directed by the apparatus
until rings of precipitation of gold particles around the tube became visible (most
clearly at the beginning of the tubing). A nitrogen flow (0.5 ml/min) was then ap-
plied to dry the DNA-coated gold particles for 15 minutes. After visual examination
of the tubing, the parts exhibiting evenly distributed DNA-coated gold particles were
cut into 1.2-cm cartridges and stored at 4°C. Per shot 0.5 µg DNA was delivered,
which was coated on 0.1 mg gold particles (DLR: 0.5, MLQ: 0.1). Loading of the
cartridge was checked by dissociation of the DNA from the gold by adding 100 µl
Tris-HCl (10 mM)/EDTA (1 mM) (pH 7.5) buffer to one cartridge followed by vig-
orous mixing and sonication. The optical density was determined and the concentra-
tion of the DNA calculated. On average, within one complete coating of tubing a
standard deviation of less than 15% was obtained. A special delivery device on top
of the gene gun was developed at our laboratory to specifically enable high efficien-
cy bombardment of 3 × 105 cardiomyocytes in a 1.8-cm2 well. Medium was first as-
pirated from the cells followed by immediate bombardment with the Helios Gene
Gun system (Biorad) at 100 psi helium pressure, then new serum-free medium was
carefully layered back on the cells.
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Northern Blotting
Total RNA was isolated by the guanidinium isothiocyanate method, quantified by
spectrometry, separated on 1% denaturing formaldehyde-agarose gels, and blotted
onto Hybond (Amersham). Probes described below were labeled by random priming
using [α-32P]dCTP (Amersham). The CAT probe was excised from the CAT reporter
plasmid.22 The glyceraldehyde phosphate dehydrogenase (GAPDH), PL, and ANF
probes were developed by RT-PCR on rat heart RNA based on published sequences.
A SERCA2 cDNA (RHCa-117) was a kind gift from Lompre.31 Hybridization was
performed as described.22 The hybridization signal was quantified by the Molecular
Imager (Biorad).
Analysis of -Gal Gene Expression
Quantification of the β-Gal protein was performed by ELISA according to the
manufacturer's protocol (Boehringer Mannheim). Histochemical staining of β-Gal
protein was performed overnight according to standard protocols. After staining,
cells were refixed and photographed. Cells staining positive for β-Gal were counted
per well. Transfection efficiencies were based on this visual examination, as well as
by comparing the obtained ELISA results to the amount of β-Gal measured (by
ELISA) after 100% infection of cardiomyocytes with an adenovirus encoding β-Gal
under the control of a Cowpea Mosaic virus promoter (results not shown).
Statistical Analysis
Significance was set at p < 0.05, Student-Newman-Keuls test, for at least four in-
dependent experiments.
RESULTS
Changes in Gene Expression in Cardiomyocytes Stimulated by ET-1
Previously, we demonstrated that 24 to 48 h ET-1 stimulation of serum-free cul-
tured cardiomyocytes led to an increase of the rate of protein synthesis and protein/
DNA mass ratio, both reminiscent of hypertrophy.9,21,22 To determine whether
ET-1–induced changes in cardiac gene expression are characteristic of hypertrophy
and heart failure in vivo, we measured the changes in expression of ANF, SERCA2,
and PL relative to GAPDH (TABLE 1). The increase in GAPDH mRNA is in accor-
dance with the general increase of total RNA content seen 48 h after stimulation with
ET-1.22 As expected, ANF and SERCA2 (including PL) expression were respective-
ly up- and downregulated. However, it should be noted that the absolute amounts of
PL and SERCA2 mRNA levels, i.e., uncorrected for GAPDH levels, did not change
significantly when compared to control.
Analysis of Transcriptional Regulation of the SERCA2 Gene
Our observation that the SERCA2 gene was downregulated in hypertrophied car-
diomyocytes is consistent with the numerous previous reports (including our own
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reports32) on reduced Ca2+ pump activity in the hypertrophied (failing) human and
animal heart in vivo (reviews1−4). To perform detailed analysis of SERCA2 promoter
regulation and identify cis-regulatory elements involved, a pure culture of cardiomy-
ocytes (e.g., free of coronary smooth muscle cells) expressing the splice variant
SERCA2a3 is essential. Furthermore, we have isolated a genomic fragment of the
SERCA2 gene containing 1.5 kb of the promoter region and 0.4 kb of the 5′ UTR,
which was subcloned into the CAT reporter plasmid (nucleotide sequences were
published by van Heugten and colleagues22). The sequence of this promoter was an-
alyzed with the Transfac database using the MatInspector program33 to detect any
putative recognition sites for transcription factors, which might be important for the
regulation of the SERCA2 promoter. FIGURE 1 represents the SERCA2 promoter-re-
porter gene construct with indicated recognition sites of putative interacting tran-
scription factors. Indeed many transcription factors (Nkx-2.5, M-CAT, and GATA-4)
known to be important for cardiac development and/or hypertrophic responses have
putative recognition sites in this promoter.34−36 To analyze the response of this pro-
moter fragment, we transfected the reporter plasmid into cardiomyocytes that were
subsequently stimulated by ET-1 to become hypertrophied. FIGURE 2 illustrates that,
also in this separate series of experiments, ET-1 induces a decrease of SERCA2/
GAPDH mRNA ratio and an increase in GAPDH mRNA level. Although only a mi-
FIGURE 2. Transcriptional regulation of SERCA2 gene in rat cardiomyocytes. The
CATSpro1.9 DNA construct was transfected into rat cardiomyocytes using DOTAP and hy-
pertrophy was induced by stimulation of the cells with 10−8 M ET-1 for 48 h. Subsequently,
mRNA levels were quantified as described in Methods. Hybridization signals are represented
relative to unstimulated control cells for GAPDH mRNA, while the (endogenous) SERCA2
and CAT mRNA signals were first corrected for increase in total RNA by expressing the ratio
of these mRNAs relative to GAPDH mRNA before calculating the increase or decrease in
expression relative to unstimulated control. GAPDH and SERCA2 expression are assessed in
untransfected (striped bars) versus transfected cardiomyocytes (cross-hatched bars). Data
represent mean ± SEM for 4−8 independent experiments. *p < 0.05.
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nority of cells are transfected by the SERCA2 promoter-reporter plasmid
pCAT-Spro1.9, the latter result proves that introduction of the SERCA2 promoter
fragment did not influence endogenous GAPDH and SERCA2 gene expression.
Transfection of pCAT-Spro1.9 to cultured cardiomyocytes followed by 48 h of hyper-
trophy induction with 10−8 M ET-1 resulted in decreased reporter CAT mRNA level
when compared to unstimulated transfected cells. Absolute CAT mRNA levels (i.e.,
uncorrected for GAPDH data) remained unchanged under these hypertrophic condi-
tions when compared to unstimulated cardiomyocytes. 
Gene Gun–Mediated Biolistic Transfection
The results in TABLE 1 and FIGURE 2 demonstrate that, as expected, it is possible
to investigate SERCA2 promoter regulation in neonatal cardiomyocytes using “tra-
ditional” transfection methods. However, these methods (liposome- and CaPO4-
based methods) are known to have very low transfection efficiencies (less than 1%,
see below). Firstly, studying promoters with very low activities may be difficult us-
ing these transfection methods. Secondly, high transfection efficiencies are required
to study physiological changes of, e.g., overexpressed SERCA2 gene expression or
PL synthesis disabled by antisense oligonucleotides, by exogenously introduced
DNA constructs in these cardiomyocytes. Therefore, we set out to develop a biolistic
technology using the recently commercially available Helios Gene Gun for in situ
bombardment of tissue. We optimized the biolistics transfection for use with a pri-
mary culture of cardiomyocytes and analyzed its efficacy by using a plasmid con-
taining the β-Gal reporter under control of the RSV promoter. Bombarded into the
cells was 0.5 µg of DNA coated onto 0.1 mg gold particles (0.6 µm diameter). Forty
eight hours after bombardment, cells were stained for β-Gal and the cellular mor-
phology examined (FIG. 3). Transfection efficiencies of maximally up to 10% of the
bombarded cells were obtained. Although we occasionally observe some cell death
in the center of the bombarded well, this is usually very limited, as checked by the
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bizomid (Sigma) test
assay for viable cells) (unpublished results). Next, we examined β-Gal expression in
bombarded cells quantitatively by ELISA and compared these results with other tra-
ditional transfection reagents (note that in the traditional methods the same low
amount of 0.5 µg DNA was also used). FIGURE 4 depicts the comparison of transfec-
TABLE 1. Changes in gene expression in cardiomyocytes stimulated by ET-1 for 48 h
mRNA Level (%) mRNA Ratio (%)
GAPDH mRNA 170 ± 18
ANF/GAPDH 247 ± 48
PL/GAPDH 51 ± 8
SERCA2/GAPDH 74 ± 7
Note: Hybridization signals are represented relative to unstimulated control cells for GAPDH
mRNA, while the ANF, PL, and SERCA2 signals were first corrected for increase in total RNA
by expressing the ratio relative to GAPDH mRNA before calculating the increase or decrease in
expression relative to unstimulated control. Data represent mean ± SEM for at least four inde-
pendent experiments. All values are significantly different from 100%.
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tion methods using the RSV β-Gal DNA construct as measured by ELISA. It is clear
that the biolistic method of transfection gives superior results compared to the tradi-
tional methods. Using more DNA for transfections with Fugene6 and CaPO4 raises
the efficiencies obtained with these methods for only the CaPO4 method, although
the amount of β-Gal measured after CaPO4 transfection is still considerably lower
compared to the biolistics results (FIG. 4). Recently, Boerhinger, the manufacturer of
FIGURE 3. β-Gal protein expression after transfection of rat cardiomyocytes with
RSV-β-Gal plasmid using gene gun biolistics. Cardiomyocytes were transfected with the bi-
olistic transfection methodology using the RSV-β-Gal plasmid. After 48 h cells were fixed
and stained histochemically for β-galactosidase activity (dark staining) to analyze the effi-
cacy of transfection. Up to 10% of the cells are transfected using the gene gun and no gross
morphology changes could be observed. Magnification = 200×.
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Fugene6, reported that, using mouse cardiomyocytes, approximately 1% of the cells
could be transfected. The new Fugene6 transfection reagent did not give any mea-
surable transfection in our test conditions (FIG. 4).
DISCUSSION
We isolated and determined the sequence of the rat SERCA2 gene 5′-regulatory
region and analyzed its function in the presence or absence of a hypertrophy induc-
ing stimulus (ET-1). This promoter region appears to contain several recognition
sites for cardiac myogenic regulatory factors, e.g., Nkx-2.5, M-CAT, and GATA-4,
which could be involved in the observed downregulation of transcription induced by
ET-1 (FIGS. 1 and 2). Transfection of the SERCA2 promoter fragment in cultured
cardiomyocytes did not change normal downregulation of the endogenous SERCA2
mRNA level during hypertrophy, showing transcription factors not becoming limited
by the introduced SERCA2 promoter fragment. A 1.5 kb 5′ regulatory region togeth-
er with 360 bp 5′ UTR dictated downregulation of a reporter gene similar to that ob-
served for the SERCA2 mRNA (FIG. 2). This suggests that (most) cis-acting
elements responsible for hypertrophy-associated downregulation of SERCA2 ex-
pression are confined to this regulatory region. Expression of the Ca2+ pump during
hypertrophy was only downregulated when compared to (increased levels of) GAP-
DH mRNA, but absolute SERCA2 mRNA amounts remained unchanged. Therefore,
FIGURE 4. Comparison of gene gun versus other vehicle-mediated gene transfer meth-
odologies. In all experiments the same plasmid (RSV-β-Gal) was used. Forty eight hours
after transfection cells are homogenized and protein expression measured by ELISA. Data
are represented as ng β-Gal/mg protein content±SEM. Cells were subjected to biolistic bom-
bardment using 0.1 mg of gold particles coated with 0.5 µg of DNA (biolistics), or trans-
fected using Fugene6, DOTAP, or CaPO4. The amount of DNA used per 1.8 cm2 well in the
transfection experiments is indicated. 
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the downregulation of the SERCA2 promoter may be interpreted as not responding
to the general increase in transcription that accompanies hypertrophy. Alterations in
mRNA stability could also be an additional regulator of mRNA levels as demonstrat-
ed by actinomycin-D mRNA stability assays of cardiomyocytes, treated with phor-
bol-12-myristate-13-acetate (PMA) to induce hypertrophy, which revealed a marked
destabilization of the SERCA2 transcript by PMA treatment.38 We showed previous-
ly that during ET-1 stimulation only PKC-ε becomes redistributed intracellularly,
whereas PMA caused redistribution of PKC-α, ε, and δ.39 Therefore, PMA might act
at more cellular sites compared to the physiological stimulus ET-1.
Recently Baker and coworkers,40 using the rabbit SERCA2 promoter, demon-
strated that an E/AT Box located at −1115 bp (corresponding to −1510 in the rat
SERCA2 promoter22,40) was important for muscle-specific activation of the
SERCA2 gene. However, when comparing the sequences of the rat and rabbit
SERCA2 promoters it is clear that this E/AT box is not conserved in the rat SERCA2
gene promoter, making this box a less likely candidate for transcriptional regulation
of the rat promoter.22 Whether this E/AT box is important in the response to hyper-
trophic stimuli has not been investigated so far in the rabbit SERCA2 promoter. 
The homology regions previously identified by comparing the rat promoter se-
quence with the human and rabbit promoter sequences22 (nt −1520 to −1310, and nt
−220 to +363 of the rat sequence) were recently also identified in the mouse
SERCA2 promoter41 (and personal communication, T.D. Reed). Transgenic mice
harboring different parts of the mouse SERCA2 promoter clearly demonstrate an im-
portant role for these homology regions41 (and personal communication, T.D. Reed).
Future studies will include the role of the homology regions in the transcriptional
regulation of the rat SERCA2 promoter and the preparation of deletion constructs of
the rat SERCA2 promoter to elucidate the importance of the identified putative tran-
scription factor binding sites. 
In this paper we also present the first results using the gene gun technology for
transient transfection of cardiomyocytes with a RSV-β-Gal construct. Using helium
pressure to propel DNA-coated gold beads into the cardiomyocytes is extremely
suitable for directly testing promoter/reporter gene DNA constructs since the trans-
fection efficiency appears to be appreciably higher compared to more traditional
transfection methods (FIG. 4). A transfection efficiency of approximately 10% of the
cells in the bombarded area can be maximally achieved. This high transfection effi-
ciency opens the possibility to test DNA constructs aimed at overexpressing or oli-
gonucleotide antisense inhibition of specific cardiac Ca2+ handling proteins (e.g.,
SR-Ca2+ pump or PL). Up to now this was only feasible using recombinant adenovi-
ruses.25−27 Several parameters had to be optimized before these results were ob-
tained. The amount of gold used per shot is limited since too much gold bombarded
into the cells causes extensive cell damage in the center of the well. The newly de-
veloped diffusion screen (Biorad) prevents cell damage in the center of the bombard-
ed area enabling possibly higher amounts of gold to be used. The helium pressure
used is relatively low compared to applications using other cell types, due to the fra-
gility of the cardiomyocytes. The most critical factor in achieving reproducible re-
sults turned out to be the production of the cartridges, we had to adapt the standard
procedure on some essential points (see Methods) and used CsCl-purified DNA,
which gave remarkably better results compared to DNA purified with the Wizard or
Qiagen kits (results not shown). 
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Taken together, we demonstrate for the first time that the hand-held gene gun is
a quick and reliable method to achieve high transfection efficiencies with primary
rat neonatal cardiomyocytes as target cells. Experiments on the 5′-flanking regions
of SERCA2 and PL genes using the gene gun transfection methodology are currently
in progress.
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